ArtVentive Medical president and chief technology officer Dr Leon Rudakov noted that chemoembolization, radioembolization particles, embolization glues and microspheres are currently delivered through a microcatheter and can lead to undesirable systemic effects as a result of traveling beyond the target treatment site.

"US and international patent applications were filed in 2013 for the development of the ArtVentive CAETT™ system which will allow controlled, localized delivery of embolic agents. The CAETT™ system will be submitted for both European and FDA regulatory approval following completion of the Company’s rigorous research and development program," Dr Rudakov added.

ArtVentive Medical CEO Jim Graham noted that the development of the CAETT system is based on the company’s EOS proprietary technology.

"This extraordinary system provides the foundation to expand the Company’s international market reach beyond the already growing ArtVentive EOS occlusion market," Graham added.

ArtVentive Medical is known for its development of the EOS (Endoluminal Occlusion System), a self-expandable catheter-based device that facilitates immediate, reliable and permanent occlusion of peripheral body lumens.

The company received the European CE Mark certification in 2013 for the EOS and is currently shipping to its expanding European distribution network while laying the foundation for launching into the US and other international markets during 2014, following regulatory approval.